MAM
FULC icon

Meeder Asset Management’s Fulcrum Therapeutics FULC Stock Holding History

Meeder Asset Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,479
Closed -$39.3K – 946
2025
Q4 		$39.3K Buy
+3,479
New +$35.4K ﹤0.01% 433
2020
Q3 		– Sell
-2,336
Closed -$43K – 2241
2020
Q2 		$43K Hold
2,336
– – ﹤0.01% 954
2020
Q1 		$28K Buy
+2,336
New +$37.4K ﹤0.01% 1113

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Meeder Asset Management's FULC Position: Q1 2026 in Review

Meeder Asset Management sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 3,479 shares — an estimated $39.3K sold.

Meeder Asset Management first reported a position in FULC in Q1 2020 and held it in 3 quarters. The position peaked at $43K in Q2 2020. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Meeder Asset Management reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Meeder Asset Management sold 3,479 Fulcrum Therapeutics shares in Q1 2026, an estimated $39.3K.
  • Meeder Asset Management first reported a position in Fulcrum Therapeutics in Q1 2020 and held it in 3 quarters.
  • Meeder Asset Management's Fulcrum Therapeutics position peaked at $43K in Q2 2020.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.